Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving
radiation therapy and chemotherapy.
PURPOSE: Randomized phase II trial to study the effectiveness of keratinocyte growth factor
in preventing oral mucositis in patients who have hematologic cancers and who are undergoing
radiation therapy and chemotherapy before autologous peripheral stem cell transplantation.